The Asia Pacific RNA Analysis Market would witness market growth of 16.1% CAGR during the forecast period (2022-2028).
Increased attention to biomarker discovery and the high demand for transcriptomes in research and development activities have caused a spike in transcriptome production. According to the National Human Genome Research Institute, a division of the National Institutes of Health (NIH), two projects—the Mouse Transcriptome Project and the Mammalian Gene Collection Initiative—created transcriptome resources for researchers all over the world.
RNA underwent a revolution with the arrival of high-throughput next-generation sequencing (NGS) technologies. The advantages of Sanger sequencing and hybridization-based microarrays, which were previously employed to measure gene expression, were greatly reduced by this technical advancement. In a typical RNA-Seq experiment, RNA is isolated, transformed into complementary DNA (cDNA), the sequencing library is prepared, and the RNA is then sequenced on an NGS platform.
Before doing RNA-Seq, however, several experimental factors that rely on the goals of the researcher should be considered. The utilization of biological and technical replicates, the level of sequencing, and the desired coverage of the transcriptome are a few of these. These experimental alternatives may occasionally have a negligible effect on the accuracy of the data.
In 2019, China responded quickly to the coronavirus disease by utilizing digital healthcare technology. The establishment of the COVID-19 digital health ecosystem has been missed in existing research, despite the technical analysis and discussion of actual digital health innovations. The primary factors that led to China's rapid implementation of digital health initiatives by COVID-19, as well as to document and disseminate the lessons discovered. The most active and strategically important segment of the healthcare sales business for multinational corporations is medical equipment.
The China market dominated the Asia Pacific RNA Analysis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,903.3 million by 2028. The Japan market is estimated to grow a CAGR of 15.4% during (2022 - 2028). Additionally, The India market would experience a CAGR of 16.8% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Reagents, Instruments and Services. Based on Technology, the market is segmented into Real Time-PCR (qPCR) Technology, Sequencing Technology, Microarray Technology and Others. Based on End-use, the market is segmented into Government Institutes & Academic Centers, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies and Contract Research Organizations (CROs). Based on Application, the market is segmented into Infectious Diseases & Pathogenesis, Epigenetics, RNA Structure & Molecular Dynamics, Development & Delivery of RNA Therapeutics, Construction of RNA Expression Atlas, Alternative RNA Splicing and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide RNA Analysis Market is Projected to reach USD 28 Billion by 2028, at a CAGR of 15.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Eurofins Scientific Group, Merck Group, and Promega Corporation.
By Product
By Technology
By End-use
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.